Glyphic Biotechnologies

TechCrunch: Glyphic Biotechnologies Raises 6M to Accelerate Protein Sequencing by Orders of Magnitude

The whole human proteome may be free to browse thanks to DeepMind, but at the bleeding edge of biotech new proteins are made and tested every day, a complex and time-consuming process. Glyphic Biotechnologies accelerates the critical but slow sequencing step, potentially cutting drug development times down by a huge amount, and the startup just raised a $6M seed to bring its clever solution to market.